571420login-checkIndependent Longitudinal Study Finds CareDx’s AlloSure Detects Early Signs of Rejection in Pediatric Kidney Transplant Patients |
NOVEMBER, 01, 2022
First Pediatric Study to Evaluate Use of AlloSure dd-cfDNA as Biomarker for Allograft BK Infection
Findings Add to Growing Body of Evidence Showing Clinical Value of AlloSure for Surveillance in Pediatric Kidney Transplant Patients
BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the results of a new study published in the Clinical Journal of the American Society of Nephrology (CJASN)1 showing that CareDx’s AlloSure® Kidney donor-derived cell-free DNA (dd-cfDNA) solution identifies early signs of allograft rejection and BK virus infection in pediatric kidney transplant patients.
Read the complete press release on CareDx.com.
571420login-checkIndependent Longitudinal Study Finds CareDx’s AlloSure Detects Early Signs of Rejection in Pediatric Kidney Transplant Patients |